Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18058707 | CHIMERIC ANTIGEN RECEPTORS BASED ON ALTERNATIVE SIGNAL 1 DOMAINS | Non-Final OA | The General Hospital Corporation |
| 18318232 | METHODS FOR TREATING HER2-NEGATIVE OR HER2-LOW CANCER | Non-Final OA | WASHINGTON UNIVERSITY |
| 17635119 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | Non-Final OA | City of Hope |
| 17870876 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | Final Rejection | Yeda Research and Development Co. Ltd. |
| 18017319 | FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN | Non-Final OA | Zymeworks BC Inc. |
| 18265079 | FUSION PROTEIN INCLUDING GLP-1 RECEPTOR AGONIST, AND ANTI-OSCAR ANTIBODY AND USE THEREOF | Non-Final OA | IMMUNOFORGE CO., LTD. |
| 18033335 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTIGEN BINDING DOMAIN SPECIFIC FOR MSLN HAVING A SPECIFICITY FOR TUMOR CELLS | Non-Final OA | Miltenyi Biotec B.V. & Co KG |
| 17985296 | Immunogenic Compositions and Vaccines in the Treatment and Prevention of Infections | Non-Final OA | Longhorn Vaccines and Diagnostics, LLC |
| 17610899 | ACTIVATABLE BISPECIFIC ANTIBODIES COMPRISING A LINKER BETWEEN THE TWO BINDING DOMAINS WHICH IS A HUMAN IMMUNOGLOBULIN HINGE REGION, OR A VARIANT THEREOF, AND USES THEREOF | Final Rejection | CENTESSA PHARMACEUTICALS (UK) LIMITED |
| 17631745 | GD2 BINDING MOLECULE | Non-Final OA | MIE UNIVERSITY |
| 17616281 | COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS | Non-Final OA | Janux Therapeutics, Inc. |
| 18326847 | COMBINATION THERAPIES FOR TREATING UROTHELIAL CARCINOMA | Non-Final OA | ALX Oncology Inc. |
| 18324056 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | Non-Final OA | Horizon Therapeutics Ireland DAC |
| 18321344 | CD28-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, METHODS OF GENERATION AND USES THEREOF | Non-Final OA | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN |
| 17787793 | Therapy for the Treatment of Cancer | Final Rejection | MacroGenics, Inc. |
| 18035891 | METHOD FOR CRYOPRESERVING ENGINEERED TREGS | Non-Final OA | QUELL THERAPEUTICS LTD |
| 17920375 | TECHNIQUE FOR PREPARING UNIVERSAL HUMANISED CAR19-DNT CELLS AND APPLICATION THEREFOR | Non-Final OA | ZHEJIANG RUIJIAMEI BIOTECH CO., LTD. |
| 17908545 | Membrane Ubiquitin ligases to target protein degradation | Final Rejection | UMC Utrecht Holding B.V. |
| 18042514 | CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS RECOGNIZING CEA | Non-Final OA | Charité - Universitätsmedizin Berlin |
| 18171909 | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Non-Final OA | Angiex, Inc. |
| 17822642 | THERAPEUTIC SINGLE DOMAIN ANTIBODY | Final Rejection | Singh Biotechnology, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy